Trevena Analyst and Investor Day 2015

107 Pages·2015·5.57 MB·English

Biased Ligands. Better Drugs.
Analyst & Investor Day
October 28, 2015
Forward looking statements
and other important cautions
TotheextentthatstatementscontainedinthispresentationarenotdescriptionsofhistoricalfactsregardingTrevena,Inc.,theyare
forward-looking statements reflecting management’s current beliefs and expectations. Forward-looking statements are subject to
known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity,
performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-
looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,”
“predicts,” “potential,” “intends,” or “continue,” or the negative of these terms or other comparable terminology. Forward-looking
statements containedinthis presentationinclude, butare not limitedto, (i) statementsregardingthe timingof anticipatedclinical
trials for our product candidates; (ii) the timing of receipt of clinical data for our product candidates; (iii) our expectations
regarding the potential safety, efficacy, or clinical utility of our product candidates; (iv) the size of patient populations targeted by
our product candidates and market adoption of our potential drugs by physicians and patients; (v) the timing or likelihood of
regulatoryfilingsandapprovals;and(vi)ourcashneedsandpotentialpaymentsunderouragreementswithAllerganplc.
Various factors may cause differences between our expectations and actual results, including unexpected safety or efficacy data,
unexpected side effects observed during preclinical studies or in clinical trials, lower than expected enrollment rates in clinical
trials, changes in expected or existing competition, feedback from regulatory agencies or changes in the regulatory environment
for our drug candidates, changes in our needs for future capital, the inability to protect our intellectual property, and the risk that
we become a party to unexpected litigation or other disputes. You should read our filings with the Securities and Exchange
Commission, includingthe Risk Factors set forthin our Annual Report onForm 10-K andour Quarterly Reports onForm 10-Q filed
with the Securities and Exchange Commission (SEC) and other filings the Company makes with the SEC from time to time,
completely and with the understanding that our actual future results may be materially different from what we expect. Except as
required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes
availableinthefuture.
2
Biased Ligands. Better Drugs.
Maxine Gowen Ph.D.
President & CEO
October 28, 2015
3
Our vision
Deliver value to patients,
providers, and payers
Treat highly prevalent
debilitating conditions
Discover & develop first-
and best-in-class drugs
4
Rasmussen et al Nature 2011
Trevena’s R&D strategy: highly differentiated NCEs
with potential to transform standards of care
Best-in-class First-in-class First-in-class
Trevena platform
optimized target optimized target new mechanism of
novel receptor
activity activity for new action
modulation mechanisms
indication
Patentable TRV130
TRV027 TRV250
NCEs TRV734
Pain: 50M patients AHF: 2.6M Migraine: 20M
in U.S. hospitals patients in US + EU patients in US + EU
IMS Charge Detail Master Claims Database, 2014 US hospital data, surgical and medical cases.
US National Hospital Discharge Survey for 2010; European Commission EUROSTAT database for 2010
5
Decision Resources PharmacorMigraine report Nov. 2014
TRV027 targets a novel mechanism at
β
the Angiotensin II type 1 receptor by engaging -arrestin
ARB (e.g. losartan) TRV027
AT1R
β
-arrestin
AT1R tail
6
Adapted from Shukla et al Nature 2014
Introducing oliceridine (a.k.a. TRV130)
http://www.ama-assn.org/ama/pub/physician-resources/medical-science.page?
INN name pending 7
Simulation of TRV130 docked to μ-opioid receptor from crystal structure 4DKL courtesy of Aaron Friedman, UCSD
Oliceridine is a novel and differentiated
molecule targeting the mu receptor
Oliceridine – first synthesized in 2010
• Unique chemical series
• Novel pharmacology
• Differentiating Phase 2 data
Morphine – first isolated in 1804
• Derivatives/analogues: hydromorphone,
oxymorphone, hydrocodone, oxycodone
• Still considered the benchmark for comparison
Fentanyl – first synthesized in 1960
• Analogues: remifentanyl, alfentanil, sufentanil
• Higher potency, shorter acting, and more dangerous
Klockgether-RadkeAP, AnasthesiolIntensivmedNotfallmedSchmerzther, May;37(5):244-9, 2002
8
Stanley TH J Pain Symptom Manage 7(3 Suppl): S3–7, 1992
Trevena’s approach to value creation
Novel New Differentiated
mechanisms molecules medicines
9
Trevena’s platform productivity:
4 NCEs in 8 years
Target Indication Lead Op. Preclinical Phase 1 Phase 2 Phase3 Ownership
CNSPortfolio
Moderate to Wholly
oliceridine μ-receptor Intravenous
severe pain owned
Moderate to Wholly
TRV734 μ-receptor Oral
severe pain owned
Wholly
TRV250 δ-receptor Migraine Oral
owned
Cardiovascular
Program
Collaborator
AngiotensinII AcuteHeart
TRV027 Intravenous
type 1 receptor Failure
U.S. composition of matter and method of use patents issued for TRV130 and TRV734 (expire 2032)
U.S. and ex-U.S. composition of matter and method of use patents issued for TRV027 (expire 2031)
10